# Supplementary File 2

| Country | Name of the Code | Website | Organisation Responsible | Date |
|---|---|---|---|---|
| **Government** | | | | |
| FR | Law No. 2011-2012 of 29 December 2011 on the Strengthening of Health Protection for Medicinal and Health Products | https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000025053440&categorieLien=id | Ministry of Health | Law enacted December 2011; first reports made public in October 2013 (on company websites and at the website of the French National Medical Council); Central database available since June 2014 |
| LV | Cabinet Regulation No. 378 Procedures for Advertising Medicinal Products and Procedures by Which a Medicinal Product Manufacturer is Entitled to Give Free Samples of Medicinal Products to Physicians | http://vvc.gov.lv/export/sites/default/docs/LRTA/MK_Noteikumi/Cab._Reg._No._378_-_Advertising_Medicinal_Products.pdf | Health Inspectorate of the Ministry of Health of the Republic of Latvia | Law enacted November 2014; first reports made public April 2016 |
| PL | Decreto-Lei n.º20/2013, de 14 de fevereiro article nº 159<br>Despacho n.º 12284/2014, de 06 outubro<br>Circular Informativa N.º 100/CD/100.20.200 Data 30/06/2016<br>Circular Informativa N.º 082/CD/100.20.200 Data: 30/05/2016<br>Circular Informativa N.º 012/CD/8.1.6. Data: 17/01/2014<br>Circular Informativa N.º 024/CD/8.1.6. Data: 14/02/2013<br>Decreto-Lei n.º 128/2013, de 5 de setembro<br>Decreto-Lei n.º 5/2017, de 6 de janeiro<br>Circular Informativa N.º 079/CD/100.20.200, de 30/06/2017<br>Circular Informativa N.º 003/CD/100.20.200, de 06/01/2017 | http://www.infarmed.pt/documents/15786/1068535/035-G1_DL_20_2013_1ALT.pdf<br>https://placotrans.infarmed.pt/documentacao/Circulares/2550025500.pdf<br>https://placotrans.infarmed.pt/documentacao/Circulares/CircularInformativa_100_30_06_2016.pdf<br>https://placotrans.infarmed.pt/documentacao/Circulares/12012368.pdf<br>https://placotrans.infarmed.pt/documentacao/Circulares/9580300.pdf<br>https://placotrans.infarmed.pt/documentacao/Circulares/8669190.pdf<br>http://www.infarmed.pt/documents/15786/1068535/035-G2_DL_128_2013_VF.pdf<br>https://placotrans.infarmed.pt/documentacao/Circulares/Decreto-Lei_5_2017.pdf | Infarmed (National Authority for Medicines and Health Products) | Effective as of 15 February 2013 |

| | | | | |
|---|---|---|---|---|
| | | https://placotrans.infarmed.pt/documentacao/Circulares/Circular_Informativa_079.pdf<br>https://placotrans.infarmed.pt/documentacao/Circulares/CI_N_003-CD-06_01_2017.pdf | | |
| **Industry Self-regulation** | | | | |
| EFPIA/Europe | EFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations | http://transparency.efpia.eu/uploads/Modules/Documents/efpia-disclosure-code-2014.pdf | European Federation of Pharmaceutical Industries and Associations | Adopted in June 2013 and amended in 2014. It mandates disclosure of transfers of value as of 30 June 2016 (for payments made in 2015) |
| DE | FSA-Transparency Codex ("Voluntary self-monitoring for the pharmaceutical industry") | http://www.pharma-transparency.eu/ | FSA (Association of Voluntary Self-Control of the Pharmaceutical Industry ) | Adopted 2014; first reports made public in 2016 |
| ES | Code of Practice for the Pharmaceutical Industry - Farmaindustria | http://www.codigofarmaindustria.org/servlet/sarfi/elcodigo.html | Farmaindustria (National Trade Association of the Spanish based pharmaceutical industry) | Transparency provisions included in the Code in 2014; first reports made public in June 2016; revised Code entered into effect in May 2016 |
| IT | Code of Conduct Farmindustria | http://www.farmindustria.it/index.php?option=com_jdownloads&Itemid=0&view=finish&cid=107349&catid=78 | Farmindustria (association of pharmaceutical companies operating in Italy) | Adopted 2014; first reports made public June 2016 |

| | | | | |
|---|---|---|---|---|
| LV | Disclosure Code | http://www.siffa.lv/uploads/etika/Kodeksi%202015/Atklatibas_kodekss_140930_EN.doc | 1) Association of International Research-based Pharmaceutical Manufacturers<br>2) Latvian Generic Medicines Association | Adopted: 2014 ; first reports made public April 2016 |
| SE | Ethical rules for the pharmaceutical industry in Sweden<br>Section 3 – Disclosure of transfers of value | In Swedish:<br>http://www.lif.se/globalassets/etik/dokument/ler-svenska-pdf-20170101.pdf<br><br>In English:<br>http://www.lif.se/globalassets/etik/dokument/ler-english-pdf-20170101.pdf | LIF (Swedish Association of the Pharmaceutical Industry) | First reports made public May 2016.<br>Member companies of LIF (the industry trade group) have also disclosed: "collaborations" with patient and patient and user advocacy and interest groups since 2005; "collaborations" with professional organisations since 2007; "collaborations" with public healthcare organisations since 2011. |
| UK | ABPI Code of Practice for the Pharmaceutical Industry | http://www.pmcpa.org.uk/thecode/Documents/Code%20of%20Practice%202016%20.pdf | ABPI (Association of the British Pharmaceutical Industry); has established the separate<br>Prescription Medicines Code of Practice Authority to implement code. | Implemented: 30/06/2016 (for payments made in 2015) |
| **Mixed (predominantly self-regulatory; multi-stakeholder board)** | | | | |
| NL | Code of Conduct for Pharmaceutical Advertising | http://cgr.nl/CGR.nl/media/CGR.nl/Gedragscode/20160706-Dutch_CoC_Pharmaceutical_Advertising-ENG-per-01072015.pdf | CGR (Foundation for the Code of Pharmaceutical Advertising) manages the Code. The Transparency Register Foundation<br>(Stichting Transparantieregister Zorg) was established in 2012 at the initiative of the the CGR to manage the register. | On 1 January 2012, the CGR implemented new rules on the disclosure of financial relations. A central database and webportal were set up and the first reports were published at the start of 2013. |

Abbreviations: DE, Germany; ES, Spain; FR, France; IT, Italy; LV, Latvia; NL, The Netherlands; SE, Sweden; UK, United Kingdom; EFPIA, European Federation of Pharmaceutical Industries and Associations.